ENANTA PHARMACEUTICALS, INC Increase (Decrease) in Income Taxes Payable
ENANTA PHARMACEUTICALS, INC (ENTA) reported Increase (Decrease) in Income Taxes Payable of -$1.39 million for the 12-month period ending 2019-09-30, per its 10-K filed 2021-11-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2021-11-24
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes payable for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes payable for the quarter ending 2019-06-30 was $0.00.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes payable for the quarter ending 2019-03-31 was -$5.86M.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes payable for the quarter ending 2018-12-31 was $4.47M, a 366.11% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes payable for fiscal 2019 was -$1.39M.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes payable for fiscal 2018 was -$7.91M, a 183.17% decline from fiscal 2017.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes payable for fiscal 2017 was $9.51M, a 1635.58% increase from fiscal 2016.
- ENANTA PHARMACEUTICALS, INC increase (decrease) in income taxes payable for fiscal 2016 was $548.00K, a 54.30% decline from fiscal 2015.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 3 month as first filed | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 6 month as first filed | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 9 month as first filed | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|---|---|---|
| 2019-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $0.00 derived: sum of 2 quarters · filed 2021-11-24 | -$5.86M derived: sum of 3 quarters · filed 2021-11-24 | -$1.39M 10-K · filed 2021-11-24 | |||
| 2019-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10 | -$5.86M derived: sum of 2 quarters · filed 2020-08-10 | -$1.39M 10-Q · filed 2020-08-10 | $0.00 derived: sum of 4 quarters · filed 2020-11-25 | |||
| 2019-03-31 | -$5.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-11 | -$1.39M 10-Q · filed 2020-05-11 | $0.00 derived: sum of 3 quarters · filed 2020-11-25 | -$5.38M derived: sum of 4 quarters · filed 2020-11-25 | |||
| 2018-12-31 | $4.47M 10-Q · filed 2020-02-10 | $5.86M derived: sum of 2 quarters · filed 2020-11-25 | $478.00K derived: sum of 3 quarters · filed 2020-11-25 | -$4.40M derived: sum of 4 quarters · filed 2020-11-25 | |||
| 2018-09-30 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25 | -$3.99M derived: sum of 2 quarters · filed 2020-11-25 | -$8.87M derived: sum of 3 quarters · filed 2020-11-25 | -$7.91M 10-K · filed 2020-11-25 | |||
| 2018-06-30 | -$5.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | -$10.26M derived: sum of 2 quarters · filed 2019-08-09 | -$9.30M 10-Q · filed 2019-08-09 | -$12.82M 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | -$4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10 | -$3.92M 10-Q · filed 2019-05-10 | -$5.90M 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $959.00K 10-Q · filed 2019-02-08 | $714.00K 10-Q · filed 2018-02-09 | |||||
| 2017-09-30 | $9.51M 10-K · filed 2019-11-27 | ||||||
| 2016-09-30 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | -$5.50M derived: sum of 2 quarters · filed 2018-11-29 | -$3.19M derived: sum of 3 quarters · filed 2018-11-29 | $548.00K 10-K · filed 2018-11-29 | |||
| 2016-06-30 | -$4.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09 | -$1.99M derived: sum of 2 quarters · filed 2017-08-09 | $1.75M 10-Q · filed 2017-08-09 | $724.00K derived: sum of 4 quarters · filed 2017-12-11 | |||
| 2016-03-31 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10 | $6.05M 10-Q · filed 2017-05-10 | $5.02M derived: sum of 3 quarters · filed 2017-12-11 | -$7.29M derived: sum of 4 quarters · filed 2017-12-11 | |||
| 2015-12-31 | $3.74M 10-Q · filed 2017-02-09 | $2.71M derived: sum of 2 quarters · filed 2017-12-11 | -$9.60M derived: sum of 3 quarters · filed 2017-12-11 | -$11.96M derived: sum of 4 quarters · filed 2017-12-11 | |||
| 2015-09-30 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | -$13.34M derived: sum of 2 quarters · filed 2017-12-11 | -$15.70M derived: sum of 3 quarters · filed 2017-12-11 | $1.20M 10-K · filed 2017-12-11 | |||
| 2015-06-30 | -$12.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | -$14.67M derived: sum of 2 quarters · filed 2016-08-09 | $2.23M 10-Q · filed 2016-08-09 | ||||
| 2015-03-31 | -$2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $14.54M 10-Q · filed 2016-05-10 | |||||
| 2014-12-31 | $16.90M 10-Q · filed 2016-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |